Screener
TG Therapeutics TGTX Long-Term Debt
Long-Term Debt at other companies
Other financials
Where this comes from
Reported directly by TG Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:LongTermDebtNoncurrent.
The source filing: TG Therapeutics’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 5:01 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001437749-26-025955
FAQ
- What is TG Therapeutics's long-term debt?
- TG Therapeutics (TGTX) reported long-term debt of $745.39M in Q2 2026.
- How has TG Therapeutics's long-term debt changed year-over-year?
- TG Therapeutics's long-term debt increased by 204.2% year-over-year, from $245.04M to $745.39M.
- What is the long-term trend for TG Therapeutics's long-term debt?
- Over 5 years (2020 to 2025), TG Therapeutics's long-term debt has grown at a 99.8% compound annual growth rate (CAGR), from $7.72M to $245.65M.
- What does long-term debt mean?
- Bonds, term loans, notes payable, and other borrowings with maturities beyond one year — the primary long-term financing source.
Ask your AI about TG Therapeutics's long-term debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude